Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of “Hold” from Brokerages

Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) has received a consensus recommendation of “Hold” from the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 1 year target price […]

Leave a Reply

Your email address will not be published.

Previous post AdvanSix (NYSE:ASIX) Trading 6.3% Higher Following Dividend Announcement
Next post Bread Financial Holdings, Inc. (NYSE:BFH) Receives $39.17 Average Price Target from Analysts